# DPP4-Inhibitors and Bone Metabolism in Diabetes

Study · id `cardio:ct-nct06770894` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06770894](<https://clinicaltrials.gov/study/NCT06770894>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06770894

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT06770894. Randomized; triple masking; primary purpose treatment. Start 2019-09-24 (actual); primary completion 2023-10-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT06770894, source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)
- Started: 2019-09-24 (actual) (ClinicalTrials.gov record NCT06770894, source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)
- Primary completion: 2023-10-10 (actual) (ClinicalTrials.gov record NCT06770894, source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)
- Completion: 2024-01-24 (actual) (ClinicalTrials.gov record NCT06770894, source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT06770894, source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06770894-2025-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: DPP4-Inhibitors and Bone Metabolism in Diabetes
- Acronym: SlowDOWN
- Condition: Osteoporosis
- Condition: Bone Loss, Postmenopausal
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): Sitagliptin 100 mg
- Intervention (Drug): Placebo Tablets
- Lead sponsor: Azienda Policlinico Umberto I
- Lead sponsor class: OTHER
- Collaborator: Agenzia Italiana del Farmaco
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial (`cardio:pubmed-41088165`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ef159945db8d7a07a492252aa7f0d2e0a597928c560524f357079f3cdaaec74d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
